This is a frequency change, not a dose change, and is preliminary (PMC12210098)
Specific Considerations for Non-Diabetics While semaglutide is traditionally used for managing type 2 diabetes, its approval for weight loss in non-diabetic patients requires careful consideration of dosage and administration
Thanks to both conferences and to Vusion for making my coverage possible, and stay tuned all week long as I interview some of the real movers and shakers in our industry, including Marks & Spencer Board Chairman Archie Norman
This is not standard practice and is generally not recommended, as both drugs work on the GLP-1 receptor and combining them would likely amplify side effects without proportional additional benefit
Importantly, according to FDA labeling, tirzepatide is not recommended in patients with severe gastrointestinal disease, including severe gastroparesis